Cargando…

GLP-1 based therapeutics: simultaneously combating T2DM and obesity

Glucagon-like peptide-1 (GLP-1) enhances meal-related insulin secretion, which lowers blood glucose excursions. In addition to its incretin action, GLP-1 acts on the GLP-1 receptor (GLP-1R) in the brain to suppress feeding. These combined actions of GLP-1R signaling cause improvements in glycemic co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heppner, Kristy M., Perez-Tilve, Diego
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367528/ https://www.ncbi.nlm.nih.gov/pubmed/25852463 http://dx.doi.org/10.3389/fnins.2015.00092

Ejemplares similares

GLP-1R Agonism Enhances Adjustable Gastric Banding in Diet-Induced Obese Rats
por: Habegger, Kirk M., et al.
Publicado: (2013)

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
por: Wang, Jing-Yue, et al.
Publicado: (2023)

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
por: Hope, David C. D., et al.
Publicado: (2021)

Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes
por: Tanday, Neil, et al.
Publicado: (2021)

[Gly²]-GLP-2, But Not Glucagon or [D-Ala²]-GLP-1, Controls Collagen Crosslinking in Murine Osteoblast Cultures
por: Mieczkowska, Aleksandra, et al.
Publicado: (2021)

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
por: Gallwitz, Baptist
Publicado: (2022)

Exploring the Regulation of Jiangtang Tiaozhi Formula on the Biological Network of Obese T2DM Complicated With Dyslipidemia Based on Clinical Transcriptomics
por: Bao, Tingting, et al.
Publicado: (2022)

Identifying advanced MAFLD in a cohort of T2DM and clinical features
por: Sanchez-Bao, Ana Maria, et al.
Publicado: (2023)

Combating Obesity With Thermogenic Fat: Current Challenges and Advancements
por: Pan, Ruping, et al.
Publicado: (2020)

Impact of GLP-1 receptor agonist versus omega-3 fatty acids supplement on obesity-induced alterations of mitochondrial respiration
por: Jansen, Kirsten M., et al.
Publicado: (2023)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

The Oral Delivery System of Modified GLP-1 by Probiotics for T2DM
por: Wang, Qing, et al.
Publicado: (2023)

A specific gut microbiota signature is associated with an enhanced GLP-1 and GLP-2 secretion and improved metabolic control in patients with type 2 diabetes after metabolic Roux-en-Y gastric bypass
por: Hernández-Montoliu, Laura, et al.
Publicado: (2023)

Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control
por: Stenlid, Rasmus, et al.
Publicado: (2023)

Emerging Role of Caveolin-1 in GLP-1 Action
por: Puddu, Alessandra, et al.
Publicado: (2021)

SUN-544 Immunologic Effects of GLP-1 Activation in Obese Adipose Tissue
por: Mashayekhi, Mona, et al.
Publicado: (2020)

Editorial: Current Challenges for Targeting Brown Fat Thermogenesis to Combat Obesity
por: Yoneshiro, Takeshi, et al.
Publicado: (2020)

GLP-1R Responsiveness Predicts Individual Gastric Bypass Efficacy on Glucose Tolerance in Rats
por: Habegger, Kirk M., et al.
Publicado: (2014)

The central GLP-1: implications for food and drug reward
por: Skibicka, Karolina P.
Publicado: (2013)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

The Role of GLP-1 Signaling in Hypoglycemia due to Hyperinsulinism
por: Danowitz, Melinda, et al.
Publicado: (2022)

Editorial: Pharmacogenomics and pharmacomicrobiomics in type 2 diabetes mellitus (T2DM)
por: Luo, Jian-Quan, et al.
Publicado: (2023)

Association of GLP1R variants rs2268641 and rs6923761 with obesity and other metabolic parameters in a Polish cohort
por: Michałowska, Joanna, et al.
Publicado: (2022)

Latest Advancements on Combating Obesity by Targeting Human Brown/Beige Adipose Tissues
por: Pan, Ruping, et al.
Publicado: (2022)

Circadian secretion rhythm of GLP-1 and its influencing factors
por: Liu, Chuanfeng, et al.
Publicado: (2022)

Obesity and Dietary Added Sugar Interact to Affect Postprandial GLP-1 and Its Relationship to Striatal Responses to Food Cues and Feeding Behavior
por: Jones, Sabrina, et al.
Publicado: (2021)

Gut microbiota: A new target for T2DM prevention and treatment
por: Liu, Lulu, et al.
Publicado: (2022)

Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison
por: Jung, Han Na, et al.
Publicado: (2022)

Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis
por: Lisco, Giuseppe, et al.
Publicado: (2022)

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
por: Knerr, Patrick J., et al.
Publicado: (2022)

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
por: Puglisi, Soraya, et al.
Publicado: (2021)

Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
por: Rowlands, Jordan, et al.
Publicado: (2018)

From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
por: Holst, Jens Juul
Publicado: (2019)

GLP-1 and Underlying Beneficial Actions in Alzheimer’s Disease, Hypertension, and NASH
por: Li, Qiu-Xuan, et al.
Publicado: (2021)

The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
por: Du, Haiyang, et al.
Publicado: (2022)

Cost of hospital treatment of type 1 diabetes (T1DM) and type 2 diabetes (T2DM) compared to the non-diabetes population: a detailed economic evaluation
por: Stedman, Mike, et al.
Publicado: (2020)

Signs of Deregulated Gene Expression Are Present in Both CD14(+) and CD14(-) PBMC From Non-Obese Men With Family History of T2DM
por: Koc, Michal, et al.
Publicado: (2021)

THU651 Testosterone Treatment And Sexual Function In Men With Or At Risk Of T2D: The T4DM Study
por: Wittert, Gary Allen, et al.
Publicado: (2023)

Advances in Knowledge of Candidate Genes Acting at the Beta-Cell Level in the Pathogenesis of T1DM
por: Pang, Haipeng, et al.
Publicado: (2020)

Association of epilepsy, anti-epileptic drugs (AEDs), and type 2 diabetes mellitus (T2DM): a population-based cohort retrospective study, impact of AEDs on T2DM-related molecular pathway, and via peroxisome proliferator-activated receptor γ transactivation
por: Tien, Ni, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_co35q15t0qds51mjnbh5a7krl9